Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
4DMedical Ltd ( (AU:4DX) ) just unveiled an announcement.
4DMedical Limited has lodged an Appendix 2A with the ASX applying for quotation of new fully paid ordinary shares that have been issued following the exercise or conversion of existing options or other convertible securities. The securities, which were issued on 24 December 2025, represent an administrative but necessary step to have these newly created shares admitted to trading on the ASX, marginally increasing the company’s quoted capital base and providing additional liquidity for existing stakeholders who exercised their convertible instruments.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is an Australian-listed medical technology company (ASX: 4DX) focused on advanced respiratory imaging solutions. The company develops and commercialises software and imaging technologies aimed at improving the diagnosis and management of lung and respiratory conditions for healthcare providers and patients.
Average Trading Volume: 4,965,931
Technical Sentiment Signal: Buy
Current Market Cap: A$2.01B
See more insights into 4DX stock on TipRanks’ Stock Analysis page.